查詢結果分析
相關文獻
- High Response and Relapse Rate in Cyclosporine-Treated Minimal Change Disease and Focal Segmental Glomerulosclerosis in Taiwanese Patients
- 日本外務省外交史料館館藏臺灣人出國護照相關資料之介紹(1897-1934)
- 臺灣人對「文化中國」孺慕情懷之興衰(1895-1950)
- 李登輝情結的政治心理與選民的投票行為
- 衛斯理神學與臺灣人經驗的關連
- Sympathetic Ophthalmia Associated with Cyclitis: Case Report
- 臺灣人口研究中心之成立與成果介紹
- Transradial Approach for Diagnosis of Cardiovascular Disease in Taiwanese Patients: Catheter Selection, Feasibility, Complications and Application
- 人民權論--慶祝世界人權宣言通過五十週年
- 臺灣人意識回憶錄的出現--國民黨文化霸權的崩解
頁籤選單縮合
題 名 | High Response and Relapse Rate in Cyclosporine-Treated Minimal Change Disease and Focal Segmental Glomerulosclerosis in Taiwanese Patients=環孢靈應用於臺灣病人罹患微細病變及局部性腎絲球硬化症之高反應與高復發率之特性 |
---|---|
作 者 | 林盈光; 吳逸文; 陳勇志; 孫樵隱; 林瑋; 吳麥斯; | 書刊名 | 臺灣腎臟醫學會雜誌 |
卷 期 | 22:2 2008.06[民97.06] |
頁 次 | 頁111-116+139 |
分類號 | 415.74 |
關鍵詞 | 環孢靈; 微細病變; 局部性腎絲球硬化症; 臺灣人; Cyclosporine; Minimal change disease; Focal segmental glomerulo-sclerosis; Taiwanese; |
語 文 | 英文(English) |
中文摘要 | 背景:環孢靈(CsA)曾應用於類固醇依賴型/不反應型之微細病變(MCD)或局部性腎絲球硬化症(FSGS)病人。然而其應用於台灣病人之臨床經驗卻相當缺乏。方法:本研究收錄從2004年至2007年,回溯分析經腎切片證實為微細病變(l5人)及局部性腎絲球硬化症(7人)之病人接受環孢靈治療,其劑量為環孢靈3mg/Kg/day及類固醇10mg/day。仔細觀察其腎功能及尿蛋白變化,同時分析其臨床反應、預後及副作用。結果:二十二位患者中,類固醇依賴型佔了十七位(77.3%),類固醇不反應型有五位(227%)。而微細病變族群中,環孢靈治療可引起緩解者有十一位(73%),只有四位病人(27%)對環孢靈反應不佳。從環孢靈治療到疾病緩解之時間平均為5.0±1.8週。但有緩解之七位病人停用環孢靈,其中六位(85.7%)都復發,而復發時間發生在停藥20.0±4.1週內。環孢靈治療局部性腎絲球硬化症病人亦有類似之結果。相較於類固醇不反應型病人,對類固醇有反應者其對環孢靈之治療明顯有較佳之反應(P<0.05)。副作用包含了多毛症(50%)、牙齦腫大(27.2)、高血壓(9.1%)及高血鉀(4.5%)。在使用環孢靈治療期間並無病患發生腎功能異常。結論:低劑量環孢靈治療類固醇依賴型/不反反應型之微細病變或及局部腎絲球硬化症病人是有效且安全的,但其停藥之後的復發率依然是相當高的。 |
英文摘要 | Background: Cyclosporine (CsA) is used in steroid-resistant and dependent minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS). The clinical experience is limited in Taiwanese patients who received a low dose of CsA combined with corticosteroid. Materials and Methods: We conducted a retrospective case series study of biopsy-proven MCD (15 patients) and FSGS (7 patients) with CsA treatment between 2004 and 2007. CsA therapy was used in steroid-resistant (SR) or steroid-dependent (SD) patients. The treatment protocol consisted of CsA 3 mg/Kg/day and prednisolone 10 mg/day. The clinical features, outcome, and adverse effects were assessed in detail. Results: Twenty-two patients received CsA therapy during the study period. Seventeen patients (77.3%) were steroid dependent (SD) and five patients (22.7%) were steroid-resistant (SR). In the MCD group, CsA therapy induced remission in eleven patients (73%). The mean duration for CsA-responsiveness was 5.0±1.8 weeks. Out of seven patients who withdrew from CsA, six patients (85.7%) relapsed wit/tin 20.2±4.1 weeks. The experience in the FSGS group was similar. The mean time to ac/sieve CsA-responsiveness was 4.6±2.7 weeks. Four of four patients (100%) relapsed within 18.6±6.2 weeks. Previous "steroid responsiveness" was the most powerful predictor of a favorable CsA response (P<0.05). Hypertrichosis, gum hypertrophy, hypertension, and transient hyperkalemia occurred in 50%, 27.2%, 9.1%, and 4.5% of patients, respectively. No patient developed renal dysfunction in the observation period. Conclusion: A low dose of CsA combined with corticosteroid is effective and safe for treatment of SD/SR patients with MCD and FSGS in Taiwan. However the relapse rate remains high after withdrawal of CsA. |
本系統中英文摘要資訊取自各篇刊載內容。